PEOPLE ON THE MOVE
EDAP TMS
The Chief Financial Officer of EDAP TMS, a French company which develops ultrasound therapies, has resigned to accept a “top management position” at an unknown, publicly-traded biotech.
Eric Soyer will remain with EDAP until August 31.
"Eric has been a key member of our leadership team for nearly ten years. During that time, he has built a highly capable finance team, and been instrumental in establishing and implementing our financial reporting policies and internal controls. We are confident in the quality of this team to ensure a seamless transition," said Marc Oczachowski, CEO.
EDAP’s lead therapy is Ablatherm, a high-intensity focused ultrasound (HIFU) treatment of localized prostate cancer. It is approved in the EU, Canada, and Mexico but not by the US FDA.
